These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 1686106)

  • 1. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.
    Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ
    Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifedipine in the treatment of tardive dyskinesia.
    Duncan E; Adler L; Angrist B; Rotrosen J
    J Clin Psychopharmacol; 1990 Dec; 10(6):414-6. PubMed ID: 1981070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia.
    Schwartz BL; Fay-McCarthy M; Kendrick K; Rosse RB; Deutsch SI
    Clin Neuropharmacol; 1997 Aug; 20(4):364-70. PubMed ID: 9260735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.
    Stedman TJ; Whiteford HA; Eyles D; Welham JL; Pond SM
    J Clin Psychopharmacol; 1991 Feb; 11(1):43-7. PubMed ID: 1674950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. off.
    Yamada K; Kanba S; Ashikari I; Ohnishi K; Yagi G; Asai M
    J Clin Psychopharmacol; 1996 Dec; 16(6):437-9. PubMed ID: 8959468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of nilvadipine in two cases of chronic schizophrenia.
    Yamada K; Ashikari I; Onishi K; Kanba S; Yagi G; Asai M
    Psychiatry Clin Neurosci; 1995 Aug; 49(4):237-8. PubMed ID: 9179944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.
    Caroff SN; Walker P; Campbell C; Lorry A; Petro C; Lynch K; Gallop R
    J Clin Psychiatry; 2007 Mar; 68(3):410-5. PubMed ID: 17388711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
    Karniol IG; Portela W
    Braz J Med Biol Res; 1982 Dec; 15(6):389-94. PubMed ID: 6135468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients.
    Reiter S; Adler L; Angrist B; Peselow E; Rotrosen J
    J Clin Psychiatry; 1989 Jan; 50(1):26-7. PubMed ID: 2562952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
    Libov I; Miodownik C; Bersudsky Y; Dwolatzky T; Lerner V
    J Clin Psychiatry; 2007 Jul; 68(7):1031-7. PubMed ID: 17685739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.
    Essali A; Deirawan H; Soares-Weiser K; Adams CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD000206. PubMed ID: 22071797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.
    Hayashi T; Yokota N; Takahashi T; Tawara Y; Nishikawa T; Yano T; Furutani M; Fujikawa T; Horiguchi J; Yamawaki S
    Int Clin Psychopharmacol; 1997 Jul; 12(4):199-205. PubMed ID: 9347380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study.
    Jus A; Villeneuve A; Gautier J; Jus K; Villeneuve C; Pires P; Villeneuve R
    Neuropsychobiology; 1978; 4(3):140-9. PubMed ID: 340975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics.
    Shenoy RS; Sadler AG; Goldberg SC; Hamer RM; Ross B
    J Clin Psychopharmacol; 1981 May; 1(3):141-5. PubMed ID: 6117584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adjunctive verapamil administration in chronic schizophrenic patients.
    Bartko G; Horvath S; Zador G; Frecska E
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(3):343-9. PubMed ID: 1677775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
    de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD
    Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.